항우울제 시장 : 세계 산업 규모, 점유율, 동향, 기회, 예측 - 약물 종류별, 질환 유형별, 약물 유형별, 지역별, 경쟁별(2020-2030년)

The Global Depression Drugs Market will grow from USD 18.46 Billion in 2024 to USD 21.79 Billion by 2030 at a 2.8% CAGR. The global depression drugs market encompasses pharmaceutical agents specifically developed to treat major depressive disorder and related mental health conditions, functioning primarily by modulating neurotransmitter activity in the brain. Key drivers bolstering this market's expansion include the escalating global prevalence of mental health disorders, a growing public awareness of these conditions leading to increased diagnoses, and continuous advancements in pharmaceutical research and development introducing novel therapeutic options.

Key Market Drivers

The increasing prevalence of depressive disorders fundamentally propels the global depression drugs market by expanding the patient population requiring pharmacological interventions. These conditions represent a substantial portion of the global disease burden, necessitating a continuous supply of effective treatments. According to the World Health Organization, in September 2025, in their 'World Mental Health Today: Latest Data' and 'Mental Health Atlas 2024' reports, over one billion people worldwide are living with mental health disorders, with anxiety and depressive disorders collectively constituting more than two-thirds of all cases.

Key Market Challenges

A significant challenge impeding the sustained growth of the global depression drugs market is the limited accessibility of mental healthcare services and essential medications, particularly within emerging economies. These regions frequently contend with inadequate healthcare infrastructure and insufficient numbers of mental health professionals. This accessibility gap directly restricts patient reach and the uptake of necessary pharmacological interventions, thereby hindering overall market expansion.

Key Market Trends

The emergence of psychedelic-assisted treatment modalities represents a significant shift in the therapeutic landscape for depression, offering novel mechanisms of action beyond conventional monoaminergic approaches. These therapies, often involving compounds like psilocybin and lysergic acid diethylamide (LSD) alongside psychological support, are demonstrating promising efficacy, particularly for treatment-resistant depression. For instance, Compass Pathways announced in June 2025 that its COMP360 psilocybin achieved the primary endpoint in a Phase 3 trial for treatment-resistant depression, showing a highly statistically significant and clinically meaningful reduction in depressive symptoms after six weeks.

Key Market Players

• Otsuka Holdings Co., Ltd.
• Pfizer, Inc.
• Eli Lilly and Company
• AstraZeneca plc.
• Novartis AG
• Bristol-Myers Squibb Company
• GlaxoSmithKline plc.
• Takeda Pharmaceutical Co., Ltd.
• AbbVie, Inc.
• Johnson & Johnson

Report Scope:

In this report, the Global Depression Drugs Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Depression Drugs Market, By Drug Class:

• Atypical Antipsychotics
• Serotonin-Norepinephrine Reuptake Inhibitors (SNRIs)
• Selective Serotonin Reuptake Inhibitors (SSRIs)
• Central Nervous System (CNS) Stimulants
• Tricyclic Antidepressants
• Monoamine Oxidase Inhibitors
• Others

Depression Drugs Market, By Disorder Type:

• Major Depressive Disorder
• Obsessive-Compulsive Disorder
• Generalized Anxiety Disorder
• Panic Disorder
• Others

Depression Drugs Market, By Drug Type:

• Generic Drugs
• Branded Drugs

Depression Drugs Market, By Region:

• North America
  • United States
  • Canada
  • Mexico
• Europe
  • France
  • United Kingdom
  • Italy
  • Germany
  • Spain
• Asia Pacific
  • China
  • India
  • Japan
  • Australia
  • South Korea
• South America
  • Brazil
  • Argentina
  • Colombia
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies presents in the Global Depression Drugs Market.

Available Customizations:

Global Depression Drugs Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

• 1.1. Market Definition
• 1.2. Scope of the Market
  • 1.2.1. Markets Covered
  • 1.2.2. Years Considered for Study
  • 1.2.3. Key Market Segmentations

2. Research Methodology

• 2.1. Objective of the Study
• 2.2. Baseline Methodology
• 2.3. Key Industry Partners
• 2.4. Major Association and Secondary Sources
• 2.5. Forecasting Methodology
• 2.6. Data Triangulation & Validation
• 2.7. Assumptions and Limitations

3. Executive Summary

• 3.1. Overview of the Market
• 3.2. Overview of Key Market Segmentations
• 3.3. Overview of Key Market Players
• 3.4. Overview of Key Regions/Countries
• 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Depression Drugs Market Outlook

• 5.1. Market Size & Forecast
  • 5.1.1. By Value
• 5.2. Market Share & Forecast
  • 5.2.1. By Drug Class (Atypical Antipsychotics, Serotonin-Norepinephrine Reuptake Inhibitors (SNRIs), Selective Serotonin Reuptake Inhibitors (SSRIs), Central Nervous System (CNS) Stimulants, Tricyclic Antidepressants, Monoamine Oxidase Inhibitors, Others)
  • 5.2.2. By Disorder Type (Major Depressive Disorder, Obsessive-Compulsive Disorder, Generalized Anxiety Disorder, Panic Disorder, Others)
  • 5.2.3. By Drug Type (Generic Drugs, Branded Drugs)
  • 5.2.4. By Region
  • 5.2.5. By Company (2024)
• 5.3. Market Map

6. North America Depression Drugs Market Outlook

• 6.1. Market Size & Forecast
  • 6.1.1. By Value
• 6.2. Market Share & Forecast
  • 6.2.1. By Drug Class
  • 6.2.2. By Disorder Type
  • 6.2.3. By Drug Type
  • 6.2.4. By Country
• 6.3. North America: Country Analysis
  • 6.3.1. United States Depression Drugs Market Outlook
    • 6.3.1.1. Market Size & Forecast
      • 6.3.1.1.1. By Value
    • 6.3.1.2. Market Share & Forecast
      • 6.3.1.2.1. By Drug Class
      • 6.3.1.2.2. By Disorder Type
      • 6.3.1.2.3. By Drug Type
  • 6.3.2. Canada Depression Drugs Market Outlook
    • 6.3.2.1. Market Size & Forecast
      • 6.3.2.1.1. By Value
    • 6.3.2.2. Market Share & Forecast
      • 6.3.2.2.1. By Drug Class
      • 6.3.2.2.2. By Disorder Type
      • 6.3.2.2.3. By Drug Type
  • 6.3.3. Mexico Depression Drugs Market Outlook
    • 6.3.3.1. Market Size & Forecast
      • 6.3.3.1.1. By Value
    • 6.3.3.2. Market Share & Forecast
      • 6.3.3.2.1. By Drug Class
      • 6.3.3.2.2. By Disorder Type
      • 6.3.3.2.3. By Drug Type

7. Europe Depression Drugs Market Outlook

• 7.1. Market Size & Forecast
  • 7.1.1. By Value
• 7.2. Market Share & Forecast
  • 7.2.1. By Drug Class
  • 7.2.2. By Disorder Type
  • 7.2.3. By Drug Type
  • 7.2.4. By Country
• 7.3. Europe: Country Analysis
  • 7.3.1. Germany Depression Drugs Market Outlook
    • 7.3.1.1. Market Size & Forecast
      • 7.3.1.1.1. By Value
    • 7.3.1.2. Market Share & Forecast
      • 7.3.1.2.1. By Drug Class
      • 7.3.1.2.2. By Disorder Type
      • 7.3.1.2.3. By Drug Type
  • 7.3.2. France Depression Drugs Market Outlook
    • 7.3.2.1. Market Size & Forecast
      • 7.3.2.1.1. By Value
    • 7.3.2.2. Market Share & Forecast
      • 7.3.2.2.1. By Drug Class
      • 7.3.2.2.2. By Disorder Type
      • 7.3.2.2.3. By Drug Type
  • 7.3.3. United Kingdom Depression Drugs Market Outlook
    • 7.3.3.1. Market Size & Forecast
      • 7.3.3.1.1. By Value
    • 7.3.3.2. Market Share & Forecast
      • 7.3.3.2.1. By Drug Class
      • 7.3.3.2.2. By Disorder Type
      • 7.3.3.2.3. By Drug Type
  • 7.3.4. Italy Depression Drugs Market Outlook
    • 7.3.4.1. Market Size & Forecast
      • 7.3.4.1.1. By Value
    • 7.3.4.2. Market Share & Forecast
      • 7.3.4.2.1. By Drug Class
      • 7.3.4.2.2. By Disorder Type
      • 7.3.4.2.3. By Drug Type
  • 7.3.5. Spain Depression Drugs Market Outlook
    • 7.3.5.1. Market Size & Forecast
      • 7.3.5.1.1. By Value
    • 7.3.5.2. Market Share & Forecast
      • 7.3.5.2.1. By Drug Class
      • 7.3.5.2.2. By Disorder Type
      • 7.3.5.2.3. By Drug Type

8. Asia Pacific Depression Drugs Market Outlook

• 8.1. Market Size & Forecast
  • 8.1.1. By Value
• 8.2. Market Share & Forecast
  • 8.2.1. By Drug Class
  • 8.2.2. By Disorder Type
  • 8.2.3. By Drug Type
  • 8.2.4. By Country
• 8.3. Asia Pacific: Country Analysis
  • 8.3.1. China Depression Drugs Market Outlook
    • 8.3.1.1. Market Size & Forecast
      • 8.3.1.1.1. By Value
    • 8.3.1.2. Market Share & Forecast
      • 8.3.1.2.1. By Drug Class
      • 8.3.1.2.2. By Disorder Type
      • 8.3.1.2.3. By Drug Type
  • 8.3.2. India Depression Drugs Market Outlook
    • 8.3.2.1. Market Size & Forecast
      • 8.3.2.1.1. By Value
    • 8.3.2.2. Market Share & Forecast
      • 8.3.2.2.1. By Drug Class
      • 8.3.2.2.2. By Disorder Type
      • 8.3.2.2.3. By Drug Type
  • 8.3.3. Japan Depression Drugs Market Outlook
    • 8.3.3.1. Market Size & Forecast
      • 8.3.3.1.1. By Value
    • 8.3.3.2. Market Share & Forecast
      • 8.3.3.2.1. By Drug Class
      • 8.3.3.2.2. By Disorder Type
      • 8.3.3.2.3. By Drug Type
  • 8.3.4. South Korea Depression Drugs Market Outlook
    • 8.3.4.1. Market Size & Forecast
      • 8.3.4.1.1. By Value
    • 8.3.4.2. Market Share & Forecast
      • 8.3.4.2.1. By Drug Class
      • 8.3.4.2.2. By Disorder Type
      • 8.3.4.2.3. By Drug Type
  • 8.3.5. Australia Depression Drugs Market Outlook
    • 8.3.5.1. Market Size & Forecast
      • 8.3.5.1.1. By Value
    • 8.3.5.2. Market Share & Forecast
      • 8.3.5.2.1. By Drug Class
      • 8.3.5.2.2. By Disorder Type
      • 8.3.5.2.3. By Drug Type

9. Middle East & Africa Depression Drugs Market Outlook

• 9.1. Market Size & Forecast
  • 9.1.1. By Value
• 9.2. Market Share & Forecast
  • 9.2.1. By Drug Class
  • 9.2.2. By Disorder Type
  • 9.2.3. By Drug Type
  • 9.2.4. By Country
• 9.3. Middle East & Africa: Country Analysis
  • 9.3.1. Saudi Arabia Depression Drugs Market Outlook
    • 9.3.1.1. Market Size & Forecast
      • 9.3.1.1.1. By Value
    • 9.3.1.2. Market Share & Forecast
      • 9.3.1.2.1. By Drug Class
      • 9.3.1.2.2. By Disorder Type
      • 9.3.1.2.3. By Drug Type
  • 9.3.2. UAE Depression Drugs Market Outlook
    • 9.3.2.1. Market Size & Forecast
      • 9.3.2.1.1. By Value
    • 9.3.2.2. Market Share & Forecast
      • 9.3.2.2.1. By Drug Class
      • 9.3.2.2.2. By Disorder Type
      • 9.3.2.2.3. By Drug Type
  • 9.3.3. South Africa Depression Drugs Market Outlook
    • 9.3.3.1. Market Size & Forecast
      • 9.3.3.1.1. By Value
    • 9.3.3.2. Market Share & Forecast
      • 9.3.3.2.1. By Drug Class
      • 9.3.3.2.2. By Disorder Type
      • 9.3.3.2.3. By Drug Type

10. South America Depression Drugs Market Outlook

• 10.1. Market Size & Forecast
  • 10.1.1. By Value
• 10.2. Market Share & Forecast
  • 10.2.1. By Drug Class
  • 10.2.2. By Disorder Type
  • 10.2.3. By Drug Type
  • 10.2.4. By Country
• 10.3. South America: Country Analysis
  • 10.3.1. Brazil Depression Drugs Market Outlook
    • 10.3.1.1. Market Size & Forecast
      • 10.3.1.1.1. By Value
    • 10.3.1.2. Market Share & Forecast
      • 10.3.1.2.1. By Drug Class
      • 10.3.1.2.2. By Disorder Type
      • 10.3.1.2.3. By Drug Type
  • 10.3.2. Colombia Depression Drugs Market Outlook
    • 10.3.2.1. Market Size & Forecast
      • 10.3.2.1.1. By Value
    • 10.3.2.2. Market Share & Forecast
      • 10.3.2.2.1. By Drug Class
      • 10.3.2.2.2. By Disorder Type
      • 10.3.2.2.3. By Drug Type
  • 10.3.3. Argentina Depression Drugs Market Outlook
    • 10.3.3.1. Market Size & Forecast
      • 10.3.3.1.1. By Value
    • 10.3.3.2. Market Share & Forecast
      • 10.3.3.2.1. By Drug Class
      • 10.3.3.2.2. By Disorder Type
      • 10.3.3.2.3. By Drug Type

11. Market Dynamics

• 11.1. Drivers
• 11.2. Challenges

12. Market Trends & Developments

• 12.1. Merger & Acquisition (If Any)
• 12.2. Product Launches (If Any)
• 12.3. Recent Developments

13. Global Depression Drugs Market: SWOT Analysis

14. Porter's Five Forces Analysis

• 14.1. Competition in the Industry
• 14.2. Potential of New Entrants
• 14.3. Power of Suppliers
• 14.4. Power of Customers
• 14.5. Threat of Substitute Products

15. Competitive Landscape

• 15.1. Otsuka Holdings Co., Ltd.
  • 15.1.1. Business Overview
  • 15.1.2. Products & Services
  • 15.1.3. Recent Developments
  • 15.1.4. Key Personnel
  • 15.1.5. SWOT Analysis
• 15.2. Pfizer, Inc.
• 15.3. Eli Lilly and Company
• 15.4. AstraZeneca plc.
• 15.5. Novartis AG
• 15.6. Bristol-Myers Squibb Company
• 15.7. GlaxoSmithKline plc.
• 15.8. Takeda Pharmaceutical Co., Ltd.
• 15.9. AbbVie, Inc.
• 15.10. Johnson & Johnson

16. Strategic Recommendations

17. About Us & Disclaimer